| 1 |
35144161 | Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors. | 2022 Apr |
1 |
| 2 |
34128532 | Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia. | 2021 Nov 2 |
2 |
| 3 |
29054076 | Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. | 2017 Nov |
1 |
| 4 |
25056761 | Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients. | 2015 Apr |
1 |
| 5 |
23394475 | Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? | 2013 Jul |
2 |
| 6 |
21212528 | Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. | 2011 |
3 |
| 7 |
21311410 | Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. | 2011 Apr |
2 |